Prof. Chang is the Chief Scientific Advisor of PhorMed. Prof. Chang is also the inventor and patent holder for indications presently being developed by PhorMed and has executive responsibility for PhorMed’s branded research and development (R&D) and medical affairs. Prof. Chang is well known within the field of oncology. During his distinguished career, he has authored 124 peer-reviewed journal publications, filed 9 patents for the treatment of cancer, inflammation, hematology, and neurological disorders, and has presented 150+ scientific abstracts. Prior to PhorMed, Prof. Chang worked at Biosuccess Biotech, Hoffman-LaRoche, Schering Corp, Burroughs Wellcome, and was director of Biochemical Pharmacology at Rutgers.

Mr. Chang is Chairman and Chief Executive Officer of PhorMed, where he leads the company’s strategic growth initiatives, oversees the advancement of its clinical development programs, and directs the continued expansion of its pipeline. He has been the driving force behind PhorMed’s patient-focused drug development model, which utilizes patient insights to inform clinical research programs focused on next-generation, innovative treatment to help people living with rare oncological diseases. Mr. Chang brings more than 30 years of executive and pharmaceutical industry experience. His background spans international banking, venture capital, mergers and acquisitions, finance, public-market transactions, and operational management. He is also a co-author of 2 patents. Prior to PhorMed, Ben held leadership roles at Rich Pharmaceuticals and Biosuccess Biotech.

Dr. Carole A. Salvador serves as the Secretary, Treasurer, and Human Resources Director at PhorMed, where she manages internal operations, oversees human resource strategies, and financial management. Dr. Salvador brings 30+ years of experience in clinical psychology, organizational consulting, and business management. She founded Affiliates in Psychology and Education, a practice specializing in clinical, coaching, and organizational consulting, and contributed to biochemical and pharmacological research at Cornell Medical School and Burroughs Welcome (now GSK).

Dr. Naylor is the Chief Medical Officer of PhorMed. He is responsible for leading R&D strategy and Medical Affairs for PhorMed as well as oversees the functional areas of Clinical Strategy and Clinical Operations. Prior to PhorMed, Dr. Naylor founded Perinatal Center and served as medical director of Perinatal Services at Little Company of Mary Hospital in Torrance, CA. Dr. Naylor received his medical degree from Creighton School of Medicine and completed his residency in Obstetrics and Gynecology at the University of California Irvine and his fellowship in Maternal Medicine at Cedars Sinai Medical Center in Los Angeles.

Steve Davis is responsible at PhorMed for all legal, governance, regulatory, risk, compliance, and EH&S matters. He also serves as a securities attorney, assisting with financial audits and reviews. Mr. Davis brings 27+ years of experience in corporate and business law. He has served on the Board of Directors of Philter Labs, Inc., and the Board and Audit, Compensation, and Nominating Committees of Telanetix, Inc. Previously, he was General Counsel and an executive officer of Molecular Imaging Corporation, as well as in-house counsel for Leap Wireless International, Inc. Earlier, he practiced corporate law at Luce, Forward, Hamilton & Scripps LLP (now Dentons), advising private and public clients.

Joseph Huffman serves as the Chief Accounting Officer (CAO) at PhorMed, where he is responsible for driving strategic financial planning and ensuring regulatory compliance with financial reporting standards, including SEC and ESG reporting, managing risk and cost controls, and overseeing corporate governance. Mr. Huffman brings 32 years of experience in finance and accounting, including 28 years as a CPA and 13+ years as a Finance Director in biotechnology. He has served as managing partner at Huffman & Huffman LLC CPA’s since 1998.

Mr. Massa has over 30 years of experience in sales, marketing, development, acquisition and licensing of Generic, Branded, Medical Device and 505B2 Pharmaceutical products from manufacturers in the United States, Europe and Asia. His sales efforts over the course of his career have generated in excess of $1B in Gross Revenue.